About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT01121575

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling path...

Lead sponsor: Pfizer•9 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•advanced non small cell lung cancer (dose escalation phase)
•acquired resistance to erlotinib or gefitinib (expansion phase)
•mandatory entrance biopsy (expansion phase)

Exclusion Criteria

•interstitial lung disease
•unstable brain metastases
•leptomeningeal disease

Related studies

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

RECRUITINGPhase 1/2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more

RECRUITINGPhase 3

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510 · Non Small Cell Lung Cancer

RECRUITINGPhase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more

RECRUITINGPhase 4

Dabrafenib and/or Trametinib Rollover Study

NCT03340506 · Melanoma, Non Small Cell Lung Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 28, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment70

Start dateAug 2010

Last updatedOct 28, 2015

Condition

Non Small Cell Lung Cancer

Locations shown

Clinical Trials Office University of Colorado Hospital (CTO)

Aurora, Colorado

DRUG SHIPMENT: University of Colorado Cancer Center

Aurora, Colorado

Rocky Mountain Lions Eye Institute

Aurora, Colorado

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2015Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions